Naser Aghdami, scientific secretary of the third national festival and international congress on stem cells and regenerative medicine, which will be held by the efforts of the stem cells sciences and technologies development headquarter, compared this round of the festival with the previous round, expressing: these two rounds are not different in generalities. The same programs will be held. However, this round more focuses on immune cell therapy in order to increase programs related to cell therapy for cancer patients.

According to Aghdami, immune cell therapy is the main goal of several cell production programs and companies. In line with this, the third national festival and international congress of stem cells and regenerative medicine has aimed to involve immune cell therapy. In this regard, he affirmed: we aimed to fully cover this issue to better use immune cell therapy in the country.

Scientific secretary of the third festival of stem cells and regenerative medicine continued: in the first and second rounds of the festival, the topics were mostly related to mesenchymal cells and other stem cells. However, this year, the more attention is on immune cell therapy, which is one of the favorite therapies in the world.

He regarded the achievement of this event the interaction between various groups of a country, increased knowledge in the society and orientation of research topics.

According to Aghdami, one of the positive aspects of this event is covering the chain of science to practice and all of the circles of this chain can be observed along side each other. Another part of the event is a congress that provides updated scientific contents and another part of the exhibition is introducing the products into the industry and market. This has increased the willingness of the enthusiasts of the field to participate in the event.

The third national festival and international congress of stem cells and regenerative medicine will be held November 24^th-December 1^st, 2018 in Iran international conference center by the efforts of the stem cells sciences and technologies development headquarter.